Previous 10 | Next 10 |
TAMPA, Fla., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 42 nd Annual J.P. Morgan Healthcare Conference at 8:15 AM PT (11:15 AM EST) on Wednesday, January 10, 2024. Live audio of the event can be accessed by visitin...
2023-12-21 20:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-12-21 07:55:30 ET More on Pacira BioSciences Pacira BioSciences: Preparing For A Pivotal Q3 Earnings Pacira wins FDA approval for two new indications of Exparel Pacira BioSciences Non-GAAP EPS of $0.72 misses by $0.06, revenue of $163.93M misses by $9M F...
-- Transformational Leader Brings Three Decades of Global Experience in Pharmaceutical and Biotechnology Product Development and Commercialization -- -- Paul J. Hastings Named Chair of the Board -- -- Dave Stack to Remain in Advisory Role through August 2025 -- TAMPA,...
2023-11-10 09:06:08 ET More on Pacira BioSciences Pacira BioSciences, Inc. 2023 Q3 - Results - Earnings Call Presentation Pacira BioSciences, Inc. (PCRX) Q3 2023 Earnings Call Transcript Pacira BioSciences: Preparing For A Pivotal Q3 Earnings Pacira BioScienc...
— EXPAREL is the only FDA-approved single-dose regional analgesic to safely demonstrate four days of superiority versus bupivacaine in two clinical studies — — New indications for use as an adductor canal block and sciatic nerve block in the popliteal fossa will...
TAMPA, Fla., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferences: Jefferies London Healthcare Conference on Tuesday, November 14 th at 11:00AM...
2023-11-02 15:00:05 ET Pacira BioSciences, Inc. (PCRX) Q3 2023 Earnings Conference Call November 02, 2023 08:30 AM ET Company Participants Susan Mesco - Head of Investor Relations Dave Stack - Chairman & Chief Executive Officer Charlie Reinhart - Chief Financ...
2023-11-02 08:04:22 ET More on Pacira BioSciences Pacira BioSciences: Preparing For A Pivotal Q3 Earnings Pacira BioSciences: Sell-Off On Pain Relief Specialist - But Recovery Not Guaranteed Pacira BioSciences: Economic Returns Languish Required Growth Rates ...
-- New ASA initiatives to advance education and innovation for the anesthesia community -- -- PDUFA action date for EXPAREL as a lower extremity nerve block on track for November 13, 2023 -- -- Conference call today at 8:30 a.m. ET -- TAMPA, Fla., Nov. 02, 2023 (GLOBE NEWS...
News, Short Squeeze, Breakout and More Instantly...
Pacira BioSciences Inc. Company Name:
PCRX Stock Symbol:
NASDAQ Market:
Pacira BioSciences Inc. Website:
TAMPA, Fla., May 10, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced the pricing of $250.0 million aggregate principal amount of convertible senior notes due 2029 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule...
TAMPA, Fla., May 08, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced that it intends to offer, subject to market and other conditions, $250.0 million aggregate principal amount of convertible senior notes due 2029 (the “notes”) in a private placement...
-- Conference call today at 4:30 p.m. ET -- TAMPA, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the first quarter of...